{"title":"辉瑞期待与巨细胞治疗公司合作开发下一代抗体-药物偶联物","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I6.1954","DOIUrl":null,"url":null,"abstract":"Highlighting its continued interest in the development of antibody-drug conjugates (ADCs), Pfizer has partnered with start-up CytomX Therapeutics to use the company’s Probody™ platform to develop multiple Probody-drug conjugates in oncology. CytomX’s Probodies are masked antibodies that remain inert in healthy tissue but which are activated by proteases in the tumour microenvironment. News of the deal comes only weeks after Pfizer discontinued a Phase III study of its ADC inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin’s lymphoma.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"127 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pfizer Looks to Next-Generation Antibody-Drug Conjugates with CytomX Therapeutics Collaboration\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2013I6.1954\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Highlighting its continued interest in the development of antibody-drug conjugates (ADCs), Pfizer has partnered with start-up CytomX Therapeutics to use the company’s Probody™ platform to develop multiple Probody-drug conjugates in oncology. CytomX’s Probodies are masked antibodies that remain inert in healthy tissue but which are activated by proteases in the tumour microenvironment. News of the deal comes only weeks after Pfizer discontinued a Phase III study of its ADC inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin’s lymphoma.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"127 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-06-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2013I6.1954\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I6.1954","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Pfizer Looks to Next-Generation Antibody-Drug Conjugates with CytomX Therapeutics Collaboration
Highlighting its continued interest in the development of antibody-drug conjugates (ADCs), Pfizer has partnered with start-up CytomX Therapeutics to use the company’s Probody™ platform to develop multiple Probody-drug conjugates in oncology. CytomX’s Probodies are masked antibodies that remain inert in healthy tissue but which are activated by proteases in the tumour microenvironment. News of the deal comes only weeks after Pfizer discontinued a Phase III study of its ADC inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin’s lymphoma.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
